Next Article in Journal
Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study)
Previous Article in Journal
The Riddle of Cetuximab-Related Skin Toxicity: 1H-NMR Sebum Analysis Revealed Dynamic Lipid Alterations Associated with Skin Toxicity Development in Metastatic Colorectal Cancer Patients
 
 
Article
Peer-Review Record

A Novel apaQTL-SNP for the Modification of Non-Small-Cell Lung Cancer Susceptibility across Histological Subtypes

Cancers 2022, 14(21), 5309; https://doi.org/10.3390/cancers14215309
by Anni Qiu 1,†, Huiwen Xu 1,†, Liping Mao 2, Buyun Xu 1, Xiaoyu Fu 1, Jingwen Cheng 1, Rongrong Zhao 3, Zhounan Cheng 1, Xiaoxuan Liu 1, Jingsheng Xu 1, Yan Zhou 1, Yang Dong 1, Tian Tian 1, Guangyu Tian 3,* and Minjie Chu 1,*
Reviewer 1:
Reviewer 2: Anonymous
Cancers 2022, 14(21), 5309; https://doi.org/10.3390/cancers14215309
Submission received: 29 September 2022 / Revised: 24 October 2022 / Accepted: 26 October 2022 / Published: 28 October 2022
(This article belongs to the Section Molecular Cancer Biology)

Round 1

Reviewer 1 Report

1) The main concern about this study is lack of evaluation of this product at the protein. It is strongly suggested that the authors widely discussed this issue. 

2) The role of clinical significance of these data should be clearly explained.

3) The possible correlation between these findings with stage and survival data should be added in the manuscript.  

4) The role of genetic background should be added in the discussion. 

 

Author Response

Dear reviewer,

      Attached please find the responses. 

Author Response File: Author Response.docx

Reviewer 2 Report

The authors have done a good job with this study. The following points to help provide more clarity for the reader

1. Introduction Line 43: Could the authors please add the global values?

2. Introduction line 45: Could the authors please indicate how the current study might help address this problem and reduce the incidence of NSCLC in the general population

3. Line 112: Could the authors indicate if the controls were only female? Could the authors also indicate why a female data set was selected for Stage I?

4. Line 115: Similarly, could the authors indicate the sex of the patients and healthy controls included in stage II of the study?

5. Figure 2: Please include a more detailed description of the 3 plots in the figure legend

6. Please include a detailed description of the figures in the legend as well.

7. Could the authors also tabulate the characteristics of the Stage II subjects in the first paragraph of the results section?

 

Author Response

Dear reviewer,

   Attached please find the responses.

Author Response File: Author Response.docx

Reviewer 3 Report

Dear authors,

Congratulations on your work and result.

Your article brings novelty for the molecular oncogenic mechanisms in NSCLC, which may become a biomarker for this disease.

The results are clearly presented, the materials and methods well described and the discussions relevant for the topic.

As a suggestion, you could replace the word „stage” with another synonym (phase?) because it can be mistaken by staging of cancer according to TNM.

The figures (particularly 2 and 4) could be a little wider because they are hard to „read”.

Moreover, the p-value in table 4 should not appear on 2 rows as it is unusual.

King regards,

Author Response

Dear reviewer,

   Attached please find the responses.

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

Accept. 

Back to TopTop